Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research?

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 3, 2012, Pages 353-387

  Hill, Esme J ^a   Nicolay, Nils H ^a   Middleton, Mark R ^b   Sharma, Ricky A ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Churchill Hospital   (United Kingdom)

Author keywords

Colorectal cancer; Gastro oesophageal cancer; Hepatobiliary cancer; Pancreatic cancer; Personalized medicine

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DNA POLYMERASE; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MICROSPHERE Y 90; OXALIPLATIN; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANAPHYLAXIS; ANASTOMOSIS LEAKAGE; ANEMIA; APOPTOSIS; ASTHENIA; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CELL KILLING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHEST INFECTION; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DIZZINESS; DNA ADDUCT; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG STRUCTURE; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; EXCISION REPAIR; FATIGUE; GASTROESOPHAGEAL CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GROWTH INHIBITION; HAND FOOT SYNDROME; HEPATOBILIARY SYSTEM CANCER; HUMAN; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; LEUKOPENIA; LINEAR ENERGY TRANSFER; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MISMATCH REPAIR; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PANCREAS METASTASIS; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; RECOMMENDED DRUG DOSE; RECTAL PAIN; RECTUM CANCER; RECTUM DISEASE; REOPERATION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STROKE; SYNCOPE; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84864950700     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.12.007     Document Type: Review

References (192)

1. Rose P.G. Chemoradiotherapy for cervical cancer. Eur J Cancer 2002, 38(2):270-278.
2. Geh J.I. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002, 38(2):300-313.
3. Pignon J.P., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355(9208):949-955.
4. Marijnen C.A.M., Kapiteijn E., van de Velde C.J.H., et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002, 20(3):817-825.
5. Karanjia N.D., Corder A.P., Bearn P., Heald R.J. Leakage from stapled low anastomosis after total mesorectal excision for carcinoma of the rectum. Br J Surg 1994, 81(8):1224-1226.
6. Vignali A., Fazio V.W., Lavery I.C., et al. Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1014 patients. J Am Coll Surgeons 1997, 185(2):105-113.
7. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987, 13(3):403-426.
8. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998, 9(10):1053-1071.
9. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 1998, 77(Suppl. 4):8-11.
10. Hermann R.M., Rave-Fränk M., Pradier O. Combining radiation with oxaliplatin: a review of experimental results. Cancer/Radiothérapie 2008, 12(1):61-67.
11. de Gramont A., Bosset J., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15(2):808-815.
12. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
13. Becouarn Y., Ychou M., Ducreux M., et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998, 16(8):2739-2744.
14. Diaz-Rubio E., Sastre J., Zaniboni A., et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998, 9(1):105-108.
15. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33(2):214-219.
16. Levi F., Misset J.L., Brienza S., et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992, 69(4):893-900.
17. Laadem A., Cvitkovic E. Oxaliplatin: a first DACH-platinum in oncology. Bull Cancer 2001, 88 Spec No:S9-S13.
18. Fischel J.L., Formento P., Ciccolini J., et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 2002, 86(7):1162-1168.
19. Alcindor T., Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011, 18(1):18-25.
20. Spalding A.C., Lawrence T.S. New and emerging radiosensitizers and radioprotectors. Cancer Investigat 2006, 24(4):444-456.
21. Rich T.A., Shepard R.C., Mosley S.T. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004, 22(11):2214-2232.
22. Shewach D.S., Lawrence T.S. Antimetabolite radiosensitizers. J Clin Oncol 2007, 25(26):4043-4050.
23. Ojima E., Inoue Y., Watanabe H., et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 2006, 16(5):1085-1091.
24. Lawrence T.S., Blackstock A.W., McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003, 13(1):13-21.
25. Lawrence T.S., Davis M.A., Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994, 29(3):519-523.
26. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
27. Steel G.G. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 1979, 5(8):1145-1150.
28. Gordon Steel G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979, 5(1):85-91.
29. Basic clinical radiobiology 2002, Arnold, London. G. Steel (Ed.).
30. Kidani Y., Inagaki K., Iigo M., Hoshi A., Kuretani K. Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. J Med Chem 1978, 21(12):1315-1318.
31. Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005, 53(1):3-11.
32. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25(2 Suppl. 5):4-12.
33. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4(4):307-320.
34. Xu L., Qu X., Zhang Y., et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett 2009, 583(5):943-948.
35. Ngan C.Y., Yamamoto H., Takagi A., et al. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 2008, 99(1):129-139.
36. Yang J., Parsons J., Nicolay N.H., et al. Cells deficient in the base excision repair protein. DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2009, 29(3):463-468.
37. Manic S., Gatti L., Carenini N., Fumagalli G., Zunino F., Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003, 3(1):21-29.
38. Mogi S., Oh D.H. [gamma]-H2AX formation in response to interstrand crosslinks requires XPF in human cells. DNA Rep 2006, 5(6):731-740.
39. Ho T.V., Schärer O.D. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Molec Mutag 2010, 51(6):552-566.
40. Rahn J.J., Adair G.M., Nairn R.S. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair. Environ Molec Mutag 2010, 51(6):567-581.
41. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodiv 2010, 7(3):543-566.
42. Masuda Y., Piao J., Kamiya K. DNA Replication-coupled PCNA mono-ubiquitination and polymerase switching in a human in vitro system. J Molec Biol 2010, 396(3):487-500.
43. Lehmann A.R., Niimi A., Ogi T., et al. Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Rep 2007, 6(7):891-899.
44. Milas L., Mason K.A., Liao Z., Ang K.K. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003, 25(2):152-167.
45. Amorino G.P., Freeman M.L., Carbone D.P., Lebwohl D.E., Choy H. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys 1999, 44(2):399-405.
46. Richmond R.C., Khokhar A.R., Teicher B.A., Douple E.B. Toxic variability and radiation sensitization by Pt(II) analogs in Salmonella typhimurium cells. Radiat Res 1984, 99(3):609-626.
47. Carde P., Laval F. Effect of cis-dichlorodiammine platinum IIand X rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981, 7(7):929-933.
48. Yang L.X., Douple E.B., Wang H.J. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 1995, 33(3):641-646.
49. Pawlik T.M., Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59(4):928-942.
50. Seiwert T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007, 4(2):86-100.
51. Folkvord S., Flatmark K., Seierstad T., Roe K., Rasmussen H., Ree A.H. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol 2008, 86(3):428-434.
52. Benzina S., Debomy F., Bergerat J.-P., et al. The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma cells. Cancer Lett 2007, 254(1):54-62.
53. Chater S., Amara S., Moussata D., et al. Differential effects of ionizing radiation and platinum-derivative chemotherapy on apoptotic pathways in testicular germ cells. Int J Radiat Biol 2007, 83(4):269-278.
54. Koivusalo R., Krausz E., Ruotsalainen P., Helenius H., Hietanen S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res 2002, 62(24):7364-7371.
55. Benzina S., Altmeyer A., Malek F., et al. High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cells. Cancer Lett 2008, 264(1):63-70.
56. Capirci C., Valentini V., Cionini L., et al. Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients. Int J Radiat Oncol Biol Phys 2008, 72(1):99-107.
57. Blackstock A.W., Hess S., Chaney S., Tepper J.E. 202 Oxaliplatin: In vitro evidence of its radiation sensitizing activity-preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 1999, 45(3 Suppl. 1):253-254.
58. Magne N., Fischel J.L., Formento P., et al. Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology 2003, 64(3):280-287.
59. Kjellstrom J., Kjellen E., Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 2005, 44:687-693.
60. Espinosa M., Martinez M., Aguilar J.L., et al. Oxaliplatin activity in head and neck cancer cell lines. Cancer Chemother Pharmacol 2005, 55(3):301-305.
61. Rave-Frã{currency sign}nk M., Schmidberger H., Christiansen H., Boll C., Lehmann J.r., Weiss E. Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells. Int J Radiat Biol 2007, 83(1):41-47.
62. Morgan M.A., Meirovitz A., Davis M.A., Kollar L.E., Hassan M.C., Lawrence T.S. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008, 1(1):36-43.
63. Khan Z., Khan N., Tiwari R.P., Patro I.K., Prasad G.B.K.S., Bisen P.S. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 2010, 96(2):267-273.
64. Cividalli A., Ceciarelli F., Livdi E., et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002, 52(4):1092-1098.
65. Goldberg R.M., Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2004, 54(Suppl. 1):S57-S64.
66. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30.
67. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22(7):1209-1214.
68. Hong T.S., Kachnic L.A. Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointest Cancer Res 2007, 1(2):49-56.
69. Minsky B.D. Combined modality therapy of resectable rectal cancer: current approaches. Techn Coloproctol 2004, 8(2):67-76.
70. Das P., Crane C. Preoperative and adjuvant treatment of localized rectal cancer. Curr Oncol Rep 2006, 8(3):167-173.
71. Klautke G., Fietkau R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. Int J Colorectal Dis 2007, 22(5):457-465.
72. Nelson H., Sargent D.J. Refining multimodal therapy for rectal cancer. N Engl J Med 2001, 345(9):690-692.
73. Mohiuddin M., Mohiuddin M.M., Marks J., Marks G. Future directions in neoadjuvant therapy of rectal cancer: maximizing pathological complete response rates. Cancer Treatment Rev 2009, 35(7):547-552.
74. Benson A.B. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007, 13(22 Pt 2):6913s-6920s.
75. Freyer G., Bossard N., Romestaing P., et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 Phase I Trial. J Clin Oncol 2001, 19(9):2433-2438.
76. Ryan D.P., Niedzwiecki D., Hollis D., et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: cancer and leukemia group B 89901. J Clin Oncol 2006, 24(16):2557-2562.
77. Loi S., Ngan S.Y.K., Hicks R.J., et al. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 2005, 92(4):655-661.
78. François E., Ychou M., Ducreux M., et al. Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. Euro J Cancer 2005, 41(18):2861-2867.
79. Rosenthal D.I., Catalano P.J., Haller D.G., et al. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys 2008, 72(1):108-113.
80. Sebag-Montefiore D., Glynne-Jones R., Falk S., Meadows H.M., Maughan T. A phase I//II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005, 93(9):993-998.
81. Reerink O., Mulder N.H., Verschueren R.C., Wiggers T., Szabo B.G., Hospers G.A. Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study. Anticancer Res 2005, 25(1B):629-633.
82. Fakih M.G., Rajput A., Yang G.Y., et al. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006, 65(5):1462-1470.
83. Glynne-Jones R., Sebag-Montefiore D., Maughan T.S., Falk S.J., McDonald A.C. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006, 17(1):50-56.
84. Rodel C., Grabenbauer G., Papadopoulos T., Hohenberger W., Schmoll H.-J., Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21:3098-3104.
85. Hospers G.A., Punt C.J., Tesselaar M.E., et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007, 14(10):2773-2779.
86. Gambacorta M.A., Valentini V., Coco C., et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004, 60(1):139-148.
87. Lupattelli M., Bellavita R., Natalini G., et al. Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study. Tumori 2006, 92(6):474-480.
88. Hong Y.S., Lee J.L., Park J.H., et al. Phase I study of preoperative chemoradiation with S-1 and oxaliplatin in patients with locally advanced resectable rectal cancer. Int J Radiat Oncol Biol Phys 2011, 79(3):684-689.
89. Czito B., Willett C., Hurwitz H., et al. Phase I study results of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced, unresectable or metastatic adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2006, 66(3):2097.
90. Czito B.G., Bendell J.C., Willett C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 2007, 68(2):472-478.
91. Kennecke H., Wong R., Berry S., et al. 6037 Bevacizumab - Capecitabine - Oxaliplatin - Radiation - REctal Cancer Trial (A-CORRECT) for locally advanced and low rectal cancers. Euro J Cancer Suppl 2009, 7(2):332.
92. Carraro S., Roca E.L., Cartelli C., et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002, 54(2):397-402.
93. Gerard J.P., Chapet O., Nemoz C., et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003, 21(6):1119-1124.
94. Aschele C., Friso M.L., Pucciarelli S., et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005, 16(7):1140-1146.
95. Feng H.Y., Li D.C., Lou R.C., Zhu Y., Liu L.Y. Preoperative chemoradiotherapy as neoadjuvant therapy for 35 patients with locally advanced lower rectal carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 2005, 8(2):125-128.
96. Pucciarelli S., Urso E., DeSalvo G.L., et al. 5-Fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. Arch Med Res 2006, 37(7):860-865.
97. Turitto G., Panelli G., Frattolillo A., et al. Phase II study of neoadjuvant concurrent chemioradiotherapy with oxaliplatin-containing regimen in locally advanced rectal cancer. Front Biosci 2006, 11:1275-1279.
98. Djellali L., Larbaoui B., Boukerche A., et al. Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol (Meeting Abstracts) 2009, 27(15S):e15108.
99. Machiels J.P., Duck L., Honhon B., et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005, 16(12):1898-1905.
100. Glynne-Jones R., Sebag-Montefiore D., Samuel L., Falk S., Maughan T., McDonald A. Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 2005, 23(16):252S.
101. Rutten H., Sebag-Montefiore D., Glynne-Jones R., et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol (Meeting Abstracts) 2006, 24(18 Suppl/):3528.
102. Rodel C., Liersch T., Hermann R.M., et al. Multicenter Phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25(1):110-117.
103. Alonso V., Lambea J., Salud A., et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal carcinoma: a phase II trial. J Clin Oncol (Meeting Abstracts) 2007, 25(18 Suppl.):4044.
104. Fakih M.G., BullardDunn K., Yang G.Y., et al. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2008, 72(3):650-657.
105. Majem M. Phase II clinical trial of weekly oxaliplatin concurrent with capecitabine plus pre-operative radiotherapy in resectable locally advanced rectal cancer. J Clin Oncol 2008, 26(15S).
106. Carlomagno C., Farella A., Bucci L., et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009, 20(5):906-912.
107. Lin J.Z., Zeng Z.F., Wu X.J., et al. Phase II study of pre-operative radiotherapy with capecitabine and oxaliplatin for rectal cancer and carcinoembryonic antigen as a predictor of pathological tumour response. J Int Med Res 2010, 38(2):645-654.
108. Wang J.P., Ding W.X., Deng Y.H., et al. Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study. Zhonghua Wei Chang Wai Ke Za Zhi 2008, 11(2):116-119.
109. Koeberle D., Burkhard R., von Moos R., et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 2008, 98(7):1204-1209.
110. Gunnlaugsson A., Anderson H., Fernebro E., et al. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study. European Journal of Cancer 2009, 45(5):807-813.
111. Fernandez-Martos C., Pericay C., Aparicio J., et al. Phase II, Randomized Study of Concomitant Chemoradiotherapy followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined. Locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 2010, 28(5):859-865.
112. Aschele C., Pinto C., Cordio S., et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol (Meeting Abstracts) 2009, 27(18S):CRA4008.
113. Aschele C., Lonardi S. Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer. J Clin Oncol 2007, 25(5):602-603.
114. Urso E., Serpentini S., Pucciarelli S., et al. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. Euro J Surg Oncol 2006, 32(10):1201-1208.
115. Enker W.E., Merchant N., Cohen A.M., et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg 1999, 230(4):544-552. discussion 552-4.
116. Zaheer S., Pemberton J.H., Farouk R., Dozois R.R., Wolff B.G., Ilstrup D. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998, 227(6):800-811.
117. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
118. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2):145-147.
119. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol 2005, 23(31):8136-8139.
120. Weiss C., Arnold D., Dellas K., et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010, 78(2):472-478.
121. Glynne-Jones R., Mawdsley S., Harrison M. Cetuximab and chemoradiation for rectal cancer-is the water getting muddy?. Acta Oncologica 2010, 49(3):278-286.
122. Bendell J., Czito B., Willett C., et al. Preliminary results of a phase I study of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced or metastatic adenocarcinoma of the rectum. Ann Oncol 2006, 17:103.
123. Czito B.G., Bendell J.C., Willett C.G., et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007, 68(2):472-478.
124. Dipetrillo T., Pricolo V., Lagares-Garcia J., et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer. J Clin Oncol 2009, 27(15):4105.
125. Gerard J., Azria D., Gourgou-Bourgade S., et al. Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol (Meeting Abstracts) 2009, 27(18S):LBA4007.
126. Roh M.S., Yothers G.A., O'Connell M.J., et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. ASCO Meeting Abstracts 2011, 29(15 Suppl.):3503.
127. Aschele C., Cionini L., Lonardi S., et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29(20):2773-2780.
128. Gerard J.P., Azria D., Gourgou-Bourgade S., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(10):1638-1644.
129. Tepper J.E., Wang A.Z. Improving local control in rectal cancer: radiation sensitizers or radiation dose?. J Clin Oncol 2010, 28(10):1623-1624.
130. Roedel C., Becker H., Fietkau R., et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. ASCO Meeting Abstracts 2011, 29(15 Suppl.):LBA3505.
131. Braendengen M., Tveit K.M., Berglund A., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26(22):3687-3694.
132. West N., Grabsch H., Treanor D., et al. Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone. J Clin Oncol (Meeting Abstracts) 2010, 28(15 Suppl.):3651.
133. Glynne-Jones R., Sebag-Montefiore D. What is the impact of the addition of oxaliplatin to 5-fluorouracil-based preoperative chemoradiation in rectal cancer?. Curr Colorectal Cancer Rep 2011, 7(1):1-4.
134. Marr R., Birbeck K., Garvican J., et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005, 242(1):74-82.
135. Gunderson L.L., Sargent D.J., Tepper J.E., et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004, 22(10):1785-1796.
136. Merkel S., Mansmann U., Siassi M., Papadopoulos T., Hohenberger W., Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001, 16(5):298-304.
137. Brown G., Daniels I.R. Preoperative staging of rectal cancer: the MERCURY research project. Recent Results Cancer Res 2005, 165:58-74.
138. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007, 25(9):1099-1106.
139. Kornmann M., Fakler H., Butzer U., Beger H.G., Link K.H. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 2000, 20(5A):3259-3264.
140. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326(24):1593-1598.
141. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46.
142. Khushalani N.I., Leichman C.G., Proulx G., et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002, 20(12):2844-2850.
143. Conroy T., Viret F., Francois E., et al. Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. Br J Cancer 2008, 99(9):1395-1401.
144. Maurel J., Cervantes A., Conill C., et al. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys 2005, 62(1):91-96.
145. Javle M.M., Yang G., Nwogu C.E., et al. Capecitabine, oxaliplatin and radiotherapy: a Phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Investigation 2009, 27(2):193-200.
146. Lorenzen S., Brucher B., Zimmermann F., et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 2008, 99(7):1020-1026.
147. Cagol M., Ruol A., Sileni V.C., et al. Multimodal treatment in locally advanced esophageal cancer: a multicenter phase II study with neoadjuvant oxaliplatin, 5-fluorouracil, leucovorin and neoadjuvant radiotherapy: preliminary results. Chir Ital 2006, 58(4):433-439.
148. Chiarion-Sileni V., Innocente R., Cavina R., et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009, 63(6):1111-1119.
149. Burmeister B.H., Walpole E.T., D'Arcy N., et al. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Invest New Drugs 2009, 27(3):275-279.
150. O'Connor B.M., Chadha M.K., Pande A., et al. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 2007, 13(2):119-124.
151. Louvet C., Andre T., Lledo G., et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002, 20(6):1512-1518.
152. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
153. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007, 96(8):1183-1190.
154. Brunner T.B., Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol 2010, 5:64.
155. Doyle T.H., Mornex F., McKenna W.G. The clinical implications of gemcitabine radiosensitization. Clin Cancer Res 2001, 7(2):226-228.
156. Desai S.P., Ben-Josef E., Normolle D.P., et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol 2007, 25(29):4587-4592.
157. Laurent S., Monsaert E., Boterberg T., et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. Ann Oncol 2009, 20(8):1369-1374.
158. Gunnlaugsson A., Anderson H., Lind P., Glimelius B., Johnsson A. Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. Radiother Oncol 2010, 95(3):292-297.
159. Moureau-Zabotto L., Phelip J.-M., Afchain P., et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a groupe coordinateur multidisciplinaire en oncologie Phase II Study. J Clin Oncol 2008, 26(7):1080-1085.
160. Kim S.H., Kwon H.C., Oh S.Y., et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009, 32(1):38-43.
161. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19(23):4298-4304.
162. Pare L., Marcuello E., Altes A., et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008, 99(7):1050-1055.
163. Bohanes P.O., Goldman B.H., Benedetti J., et al. Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage I-II esophageal adenocarcinoma (EA) patients treated with pre-operative platinum based chemoradiation (CRT) in a phase II co-operative study SWOG 0356. J Clin Oncol 2011, 29(4S).
164. Xu Z., Chen Z.P., Malapetsa A., et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002, 13(5):511-519.
165. Yin M., Yan J., Martinez-Balibrea E., et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011, 17(6):1632-1640.
166. Albertella M.R., Green C.M., Lehmann A.R., O'Connor M.J. A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005, 65(21):9799-9806.
167. Cruet-Hennequart S., Villalan S., Kaczmarczyk A., O'Meara E., Sokol A.M., Carty M.P. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle 2009, 8(18):3039-3050.
168. Chen Y.-w., Cleaver J.E., Hanaoka F., Chang C.-f., Chou K.-m. A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents. Molec Cancer Res 2006, 4(4):257-265.
169. Vaisman A., Masutani C., Hanaoka F., Chaney S.G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human dna polymerase η†. Biochemistry 2000, 39(16):4575-4580.
170. Wang H., Wu W., Wang H.-W., et al. Analysis of specialized DNA polymerases expression in human gliomas: association with prognostic significance. Neuro-Oncology 2010, 12(7):679-686.
171. Pan Q., Fang Y., Xu Y., Zhang K., Hu X. Down-regulation of DNA polymerases [kappa], [eta] [iota], and [zeta] in human lung, stomach, and colorectal cancers. Cancer Lett 2005, 217(2):139-147.
172. Teng K.Y., Qiu M.Z., Li Z.H., et al. DNA polymerase eta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med 2010, 8:p126.
173. Flatmark K., Ree A.H. Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. J Clin Oncol 2010, 28(29):e577-e578. author reply e581-3.
174. Mohiuddin M., Mohiuddin M.M. Neoadjuvant chemoradiation in rectal cancer: time to start in a new direction. J Clin Oncol 2011, 29(12):e352-e353. p. e350-1; author reply.
175. Giaccia A., Weinstein R., Hu J., Stamato T.D. Cell cycle-dependent repair of double-strand DNA breaks in a gamma-ray-sensitive Chinese hamster cell. Somat Cell Mol Genet 1985, 11(5):485-491.
176. Maity A., McKenna W.G., Muschel R.J. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol 1994, 31(1):1-13.
177. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338.
178. Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11(9):835-844.
179. Hartley A., Ho K.F., McConkey C., Geh J.I. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005, 78(934):934-938.
180. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797-805.
181. zum Buschenfelde C.M., Herrmann K., Schuster T., et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011, 52(8):1189-1196.
182. Rödel C., Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlentherapie Onkologie 2007, 183(5):227-235.
183. Glynne-Jones R., Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?. J Clin Oncol 2007, 25(33):5281-5286.
184. Glynne-Jones R., Grainger J., Harrison M., Ostler P., Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. Br J Cancer 2006, 94(3):363-371.
185. Wibe A., Rendedal P.R., Svensson E., et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002, 89(3):327-334.
186. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373(9666):811-820.
187. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008, 26(2):303-312.
188. Gunnlaugsson A., Nilsson P., Kjellen E., Johnsson A. The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay. Radiat Oncol 2009, 4(1):61.
189. Gunnlaugsson A., Kjellen E., Nilsson P., Bendahl P.-O., Willner J., Johnsson A. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiation in locally advanced rectal cancer. Acta Oncol 2007, 46:937-944.
190. Guerrero Urbano M.T., Henrys A.J., Adams E.J., et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006, 65(3):907-916.
191. Aristu J.J., Arbea L., Rodriguez J., et al. Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2008, 71(3):748-755.
192. Bassett E., King N.M., Bryant M.F., et al. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res 2004, 64(18):6469-6475.